A biomedical perspective of pyocyanin from Pseudomonas aeruginosa: its applications and challenges.

Pyocyanin is a bioactive pigment produced by Pseudomonas aeruginosa. It is an important virulence factor that plays a critical role in P. aeruginosa infections as a redox-active secondary metabolite and a quorum sensing (QS) signaling molecule. Pyocyanin production from chorismic acid requires the involvement of two homologous operons, phz1 and phz2, which are activated by QS regulatory proteins. Pyocyanin inhibits the proliferation of bacterial, fungal, and mammalian cells by inducing oxidative stress due to which it acts as a potent antibacterial, antifungal, and anticancer agent. Its potential role as a neuroprotectant needs further exploration. However, pyocyanin exacerbates the damaging effects of nosocomial infections caused by P. aeruginosa in immunocompromised individuals. Further, cystic fibrosis (CF) patients are highly susceptible to persistent P. aeruginosa infections in the respiratory system. The bacterial cells form colonies and three interconnected QS networks-pqs, las, and rhl-get activated, thus stimulating the cells to produce pyocyanin which exacerbates pulmonary complications. As an opportunistic pathogen, P. aeruginosa produces pyocyanin to impede the recovery of injuries like burn wounds through its anti-proliferative activity. Moreover, pyocyanin plays a vital role in compounding P. aeruginosa infections by promoting biofilm formation. This review begins with a brief description of the characteristics of pyocyanin, its activity, and the different aspects of its production including its biosynthesis, the role of QS, and the effect of environmental factors. It then goes on to explore the potential applications of pyocyanin as a biotherapeutic molecule while also highlighting the biomedical challenges and limitations that it presents.

Probiotics and Paraprobiotics: Effects on Microbiota-Gut-Brain Axis and Their Consequent Potential in Neuropsychiatric Therapy.

Neuropsychiatric disorders are clinical conditions that affect cognitive function and emotional stability, often resulting from damage or disease in the central nervous system (CNS). These disorders are a worldwide concern, impacting approximately 12.5% of the global population. The gut microbiota has been linked to neurological development and function, implicating its involvement in neuropsychiatric conditions. Due to their interaction with gut microbial communities, probiotics offer a natural alternative to traditional treatments such as therapeutic drugs and interventions for alleviating neuropsychiatric symptoms. Introduced by Metchnikoff in the early 1900s, probiotics are live microorganisms that provide various health benefits, including improved digestion, enhanced sleep quality, and reduced mental problems. However, concerns about their safety, particularly in immunocompromised patients, warrant further investigation; this has led to the concept of "paraprobiotics", inactivated forms of beneficial microorganisms that offer a safer alternative. This review begins by exploring different methods of inactivation, each targeting specific cellular components like DNA or proteins. The choice of inactivation method is crucial, as the health benefits may vary depending on the conditions employed for inactivation. The subsequent sections focus on the potential mechanisms of action and specific applications of probiotics and paraprobiotics in neuropsychiatric therapy. Probiotics and paraprobiotics interact with gut microbes, modulating the gut microbial composition and alleviating gut dysbiosis. The resulting neuropsychiatric benefits primarily stem from the gut-brain axis, a bidirectional communication channel involving various pathways discussed in the review. While further research is needed, probiotics and paraprobiotics are promising therapeutic agents for the management of neuropsychiatric disorders.

Evaluation of physicochemical properties of citric acid crosslinked starch elastomers reinforced with silicon dioxide.

Thermoplastic starch (TPS), derived from renewable resources, offers advantages such as biodegradability and lower production costs compared to petroleum-based plastics. However, its limited mechanical properties pose a challenge for broader applications. This research aims to explore the potential of enhancing the mechanical and barrier properties of TPS films through the incorporation of silicon dioxide as a reinforcement filler and citric acid as a crosslinking agent. By introducing silicon dioxide as a reinforcement filler, the mechanical strength of the TPS films is expected to be improved. Additionally, the incorporation of citric acid as a crosslinking agent is anticipated to enhance the barrier properties of the films. The combination of these additives holds promise for creating TPS films with improved performance, contributing to the development of sustainable and environmentally friendly materials in various industries. The results reveal that SiO2 improves the stiffness of the films at lower concentrations but causes brittleness at higher concentrations. In contrast, citric acid crosslinked films exhibit improved flexibility and density. Scanning electron microscopy demonstrates the morphological changes in the films, with SiO2 affecting surface roughness and aggregate formation. SiO2 reduces film thickness and transparency, while citric acid enhances water resistance and barrier properties. X-ray diffraction analysis shows a reduction in crystallinity due to the plasticization process. Fourier-transform infrared spectroscopy highlights chemical changes and antimicrobial activity is observed with citric acid against specific bacteria. The soil burial test reveals that citric acid crosslinked films exhibit slower degradation due to antimicrobial properties. The combination of SiO2 reinforcement and citric acid crosslinking enhances the overall performance of the films, promising sustainable and environmentally friendly materials for various applications.